In human heart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated, and in vitro studies suggest that it enhances myofilament calcium sensitivity and alters calpain-mediated cTnI proteolysis. However, how its hyperphosphorylation affects cardiac function in vivo remains unknown.
S
arcomeric proteins are the major components of the contractile apparatus of heart muscle. Cardiac muscle contraction is a result of myosin in the thick filament interacting with actin in the thin filament to form a force-generating cross-bridge, which is regulated by cyclic Ca 2+ concentration changes in cytosol. 1 The molecular regulators of this Ca 2+ dependent muscle activation are Tn (troponin) and Tm (tropomyosin), located on thin filament. Tn consists of 3 subunits; TnI is the inhibitory subunit, which functions via interactions with the Ca 2+ -binding subunit, the Tm-binding subunit, and Tm to inhibit myosin-actin interaction during diastole when [Ca 2+ ] is low and to switch on the contractile machinery during systole when [Ca 2+ ] increases and binds to Ca 2+ -binding subunit. 2 cTnI (cardiac TnI) is the cardiac-specific isoform of TnI and the only TnI isoform expressed in adult hearts.
The protein has 210 amino acid residues in human and is highly conserved across species. 3, 4 The cTnI knockout is lethal because of severe diastolic dysfunction. 5 Post-translational modifications of cTnI regulate cardiac function in response to physiological and pathological stresses. 6, 7 For example, phosphorylation of cTnI Ser22/23, primarily mediated by protein kinase A (PKA), enhances Ca 2+ disassociation from cardiac Ca
2+
-binding subunit and increases the amount of Ca 2+ required for generating submaximal force (this is referred to as decreasing myofilament Ca 2+ sensitivity), and therefore contributes to the enhanced relaxation rate mediated by β-adrenergic stimulation during exercise and stress. 6 Additionally, cTnI proteolysis occurs with ischemia/reperfusion (I/R) injury; the truncated cTnI lacking the distal C terminal fragment is incorporated in the myofilament contributing to I/R related cardiac dysfunction. 8 Recent detailed phosphoproteomic studies of human heart failure (HF), myocardium have revealed a novel phosphorylation site on human cTnI at Ser199, which is 2-fold hyperphosphorylated in HF compared with normal donor hearts. 9 The phosphorylation level of this site is also significantly increased in a dog model of dyssynchronous HF and restored to normal level after resynchronization therapy. 9 The site is also highly conserved across species from frog to human 10 suggesting high selection pressure. It is physically located at the cTnI distal C terminus, a highly mobile region that is crucial for the kinetics of thin filament regulation. 11, 12 More than 40% of the known cardiomyopathy-related cTnI mutations are within this region. 13 Furthermore, this site is within a peptide cleaved from cTnI via proteolysis after I/R injury. 7 Therefore, whether and how human cTnI Ser199 hyperphosphorylation affects cardiac function in vivo is of great interest. The present study addresses this question by studying 2 novel transgenic mouse models, a phospho-mimetic model and a phospho-silenced model. We examined cardiac function of both models at rest, under conditions of rate and adrenergic stress, and after I/R.
METHODS

Animal Models
The transgenic mouse model cTnIS200D overexpresses cTnI Ser200Asp mutation (cTnI Ser200 in mouse sequence is equivalent to cTnI Ser199 in human sequence) to mimic the site-specific hyperphosphorylation in vivo. The other transgenic model cTnIS200A overexpresses cTnI Ser200Ala mutation to create a nonphosphorylatable site. Both transgenes were cloned into the downstream of a cardiac-specific α-myosin heavy chain promoter (a kind gift from Dr Jeffrey Robbins, Children's Hospital Medical Center, Cincinnati, OH). After 6 generations of breeding with wild-type C57BL/6 mice, 5-to 6-month old-male transgenic mice were used and compared with their nontransgenic (NTG) siblings. All protocols about animal use were approved by Johns Hopkins University Animal Care and Use Committee.
WHAT IS NEW?
• In human heart failure (HF), cardiac troponin I (cTnI) is hyperphosphorylated. In vitro studies suggest this phosphorylation increased calcium sensitivity and alters TnI breakdown by proteolysis. • This study tested whether these mechanisms hold in an in vivo model, using transgenic mouse models of hyper-and hypo-phosphorylation at amino acid Ser200 of mouse cTnI (equivalent to the human site phosphorylated in HF).
• Cardiac-specific expression of cTnI Ser200Asp in mice, a phospho-mimic, is sufficient to reduce ventricular relaxation. Systolic function was unchanged at baseline. However, there was concomitant diminished systolic reserve in mice with cTnI during chronotropic and catecholamine stimulation.
• In addition, this phospho-mimic was associated with decreased cTnI breakdown and less ischemicreperfusion injury.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The results indicate that excessive phosphorylation of human cTnI Ser199 may reduce cardiac function, likely through increased sensitivity to Ca 2+ in the myocardial contractile apparatus with resulting impaired relaxation, and via altered interactions between troponin and actin on the thin filament. This phosphorylation may also impair contractile reserve.
• The study provides new functional insights into the post-translational regulation of cTnI and its potential role in human HF.
• The preserved EF, diastolic dysfunction, and lack of systolic reserve in this mouse model have implications for cTnI phosphorylation as a potential mechanism and novel therapeutic target in HF with preserved ejection fraction.
Echocardiography
Echocardiography studies were performed on conscious nonanesthetized mice by using a Vevo 2100 high-resolution in vivo imaging system with 40 MHz transducer (VisualSonics, Toronto, ON, Canada) and analyzed with an Advanced cardiovascular package software (VisualSonics).
In Vivo Hemodynamics
Mice were ventilated with 6 to 7 μL/g tidal volume, 130 breaths/min and anesthetized by either isofluorane (1%-2%) or intraperitoneal injection of etomidate (250 µg/kg), urethane (30 mg/kg), and morphine (15 µg/kg). Continuous pressurevolume data from left ventricle (LV) at baseline and then under varied stresses was recorded by using a 1.4F PV catheter (SPR 839; Millar Instruments Inc) as described previously. 14 An atrial/ ventricular pacing wire was placed into the esophagus and connected to a Grass stimulator for heart rate control. Transient inferior vena cava occlusion was used to derive pressure-volume relations for analysis of cardiac function.
Cardiac Muscle Isometric Force Measurements
Mice were euthanized with pentobarbital (50 mg/kg) and heparinization (100 U). As described previously, 15, 16 right ventricular trabeculae were dissected and mounted between a customized force transducer (AEM 801, SensoNor) and a motor arm, superfused with modified Krebs-Henseleit solution (in mmol/L: NaCl 120, Na 2 HCO 3 20, KCl 5, MgCl 2 1.2, glucose 10, and CaCl 2 , pH 7.35-7.40) equilibrated with 95% O 2 and 5% CO 2 at 20 to 22°C, stimulated at 0.5 Hz. The sarcomere was set and maintained at an optimal length corresponding to 2.2 to 2.3 µm as determined by laser diffraction.
Myofilament Proteins Analysis
Myofilament proteins were extracted from freshly dissected ventricles as described previously. 17 The expression level of mutant proteins cTnI Ser200Asp and cTnI Ser200Ala in hearts was assessed by Western blotting using 2 monoclonal antibodies (McAb). McAb 8I-7 (epitope cTnI 137-148 , 1:5000; International Point of Care Inc, Canada) can detect wild-type cTnI, cTnI Ser200Asp, and cTnI Ser200Ala; while McAb P45-10 (epitope cTnI 195-203, 1:5000; HyTest Ltd) cannot recognize cTnI Ser200Asp and has a much lower affinity for cTnI Ser200Ala than wild-type cTnI.
A quantitative mass spectrometry approach called multiple reaction monitoring was used to quantify the phosphorylation level of endogenous wild-type cTnI at Ser200 in heart according to the published procedures. 9 The standard peptide NITEIADLTQK and its heavy labeled version NITEIADLTQK* were used to quantify total cTnI; the standard peptide NIDAL(p) SGMEGR and its heavy labeled version NIDAL(p)SGMEGR* was used to quantify endogenously phosphorylated cTnI at Ser200. The pan-protein phosphorylation levels of myofilament proteins were determined via Pro-Q Diamond gel staining followed by SYPRO Ruby protein gel stain (Molecular Probes) according to the manufacturer's protocols. To determine the phosphorylation level of cTnI at Ser23 and Ser24, the myofilament proteins were treated with PKA catalytic subunit from bovine heart (Sigma-Aldrich, protein: enzyme=5 µg: 1 unit) at 30°C for 30 minutes in a reaction buffer containing (in mmol/L) MOPS 20, KCl 200, MgCl 2 10 and DTT 1. The phosphorylation of cTnI Ser23 and Ser24 was detected via Phospho-TnI (Cardiac; Ser23/24) antibody (1:1000; Cell Signaling).
Global I/R With Langendorff System and cTnI Cleavage Analysis
Mice were euthanized with pentobarbital (50 mg/kg), and the hearts were rapidly excised and retrogradely perfused with Krebs-Henseleit buffer (37°C) gassed with 95% O 2 and 5% CO 2 . The function of isolated heart was monitored with a water-filled balloon connected to a pressure transducer according to the published methods. 18 After stabilization, the heart was subjected to 30-minute global ischemia followed by 1-hour reperfusion and then quickly removed, frozen with liquid nitrogen, and stored at −80°C for later use. cTnI and its degradation fragments were detected by McAb 8I-7 via Western blot in whole heart homogenate.
Statistical Analysis
One-way ANOVA followed by Tukey post hoc test was used to analyze mutant protein expression, phosphorylation of myofilament proteins, cTnI degradation, and basal cardiac/ muscle function between the 3 groups. Analysis of cardiac functional responses to pacing rates or isoproterenol was done with 2-way ANOVA mixed design followed by Tukey post hoc test. Levene test and Welch correction were used to check the homogeneity of variance and analyze the data with heterogeneity of means, respectively. Values are presented as mean±SEM, and P<0.05 indicates significance.
RESULTS cTnI Mutants Were Incorporated Into Myofilaments of Transgenic Mice
Transgenic mice reproduced normally and were viable beyond 12 months of age. With 2 cTnI McAbs, McAb 8I-7 (epitope cTnI [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] ) and McAb P45-10 (epitope cTnI 195-209) , we were able to differentiate the mutant cTnI Ser200Asp and cTnI Ser200Ala from wild-type cTnI via Western blot and thus quantify the expression level of mutant cTnI in transgenic mouse hearts. The results showed that ≈88±8% of cTnI in cTnIS200D heart was replaced by mutant protein cTnI Ser200Asp, whereas ≈75±6% of cTnI in cTnIS200A heart was replaced by mutant protein cTnI Ser200Ala ( Figure 1A and 1B). We further quantified the cTnI phosphorylation at Ser200 and total cTnI (including both wild-type and mutant cTnI) via a quantitative mass spectrometry approach called multiple reaction monitoring and found that the ratio of phosphorylated cTnI at Ser200 to total cTnI was not altered in either transgenic mice as compared with the NTG littermates, indicating that neither pseudophosphorylation (cTnI Ser200Asp) nor phosphorylation-silenced (cTnI Ser200Ala) mutation affected the endogenous phosphorylation of cTnI at Ser200 ( Figure 1C ; Figure I in the Data Supplement).
TnI Ser200 Pseudophosphorylation Mice Showed Normal Histology but Impaired Relaxation on Echocardiography
At the age of 6 months, both cTnIS200D and cTnI-S200A mice had normal heart mass, LV chamber size, and wall thickness as detected by echocardiography (Table 1) . Histological examination confirmed normal cardiac structure in both transgenic models ( Figure II in the Data Supplement).
LV functional data obtained by using a parasternal short-axis echocardiographic imaging in conscious mice showed that cTnIS200D mice had normal ejection fraction (EF) but significantly prolonged isovolumic relaxation time as compared with NTG at similar heart rates ( Table 1 ). In addition, Tissue Doppler imaging demonstrated that early diastolic myocardial relaxation velocity (E′) of cTnIS200D hearts was significantly lower than in NTG ( Table 1 ). The functional data obtained with echocardiography indicate that cTnIS200D hearts, which mimic hyperphosphorylation, have normal systolic but impaired diastolic function. cTnIS200A mice displayed normal LV function, based on all echocardiographic measurements, indicating that hypophosphorylation of cTnI Ser200 does not alter cardiac function at baseline in mice.
TnI Ser200 Pseudophosphorylation Model Demonstrated Diastolic Dysfunction With Preserved EF in Hemodynamic Studies
Pressure-volume analysis is summarized in Table 2 . Under basal conditions, cTnIS200D displayed comparable heart rates, preload (end-diastolic volume, EDV), and afterload (arterial elastance) to NTG controls. cTnIS200D S200A), and thus demonstrated the total cTnI in myofilament homogenate. McAb P45-10 recognizes WT cTnI but not cTnI S200D and has a very low affinity for cTnI S200A (≈ 20% of its affinity for WT cTnI). Purified human recombinant cTnI variants were used as positive control. B, The estimated ratio of mutant cTnI to total cTnI, n=5. *P<0.05 compared with cTnIS200D group. C, Quantitative data of cTnI phosphorylation at Ser200 in the hearts of nontransgenic (NTG), cTnIS200D, and cTnIS200A mice. n=5. hearts had preserved EF and normal dP/dt max (the maximal rate of pressure rise). To better assess the overall contractility, the slope of the relationship between stroke work and preload, termed preload recruitable stroke work, was measured from variably preloaded cardiac cycles. Preload recruitable stroke work was unchanged between controls and cTnIS200D hearts. However, all relaxation parameters in cTnIS200D were abnormal. cTnIS200D had a less negative peak rate of pressure fall (dP/dt min ), prolonged isovolumic relaxation time (τ), and slower peak filling rate (PFR/EDV). As in the echocardiographic studies, there were no differences between cTnIS200A and NTG mice in either systolic or diastolic function detected by in vivo pressure-volume analysis. Those data indicate that hyperphosphorylation rather than hypophosphorylation of cTnI Ser200 impairs diastolic function but preserves EF and the overall contractility, which agrees with the echocardiography findings. It was notable that the systolic indexes that were more impacted by contractile kinetics, such as dP/dt max / iP (maximal rate of pressure rise normalized to instantaneous pressure at the same time during isovolumic contraction) and Power max /EDV (maximal ventricular power normalized to preload during LV ejection), were altered in the cTnIS200D heart versus controls although the overall EF was normal in cTnIS200D hearts.
TnI Ser200 Pseudophosphorylation Model Slowed Force Decay in Isolated Muscle Studies
To assess whether the chamber-level changes represented alterations in the muscle, we tested force development of the trabecular muscle isolated from right ventricles of mice. As shown in Figure 2 , muscles from cTnIS200D hearts developed similar peak force and take a similar time to reach the peak force relative to NTG, but relaxation was significantly slower. Consistent with the in vivo findings, muscles from cTnIS200A hearts behaved normally during force development.
Force-Frequency Relationship Was Blunted in the TnI Ser200 Pseudophosphorylation Model
To assess whether alterations in TnI Ser200 (pseudoor silenced phosphorylation) impacted cardiac reserve mechanisms, we examined heart function with incremental heart pacing rates. As expected, trabecular muscle from NTG hearts displayed a positive force-frequency relation ( Figure 3A) . However, the relationship was significantly blunted in cTnIS200D muscle. On the contrary, isometric relaxation of trabecular muscles from NTG and both TG mice was enhanced with increasing pacing rates in the similar fashion ( Figure 3B ). Similar analysis was performed in situ with heart rate ranging from 400 to 700 beats per minute. cTnIS200D mice had enhanced isovolumic contraction (reflected by dP/dt max /iP) and isovolumic relaxation (reflected by dP/dt min and τ), in agreement with the in vitro data of isometric measurements of muscle function ( Figure 3C and 3E). Although the in vitro muscle measurements were done at fixed length, in vivo muscle length changes during the ejection and ventricular filling phases of the cardiac cycle. During those 2 phases, cardiac muscle function is reflected by Power max /EDV and PFR/ EDV, respectively. cTnIS200D mice failed to enhance either Power max /EDV or PFR/EDV to the same extent as NTG ( Figure 3D and 3F) . As a result, when heart rate increased from 400 to 700 beats per minute, cTnIS200D End-diastolic volume presents preload. Arterial elastance is a measure of afterload. dP/dt max indicates peak rate of pressure rise; dP/dt max /iP, peak rate of pressure normalized to instantaneous pressure, a preload-independent index of contractility during isovolumic contraction; dP/dt min , peak rate of pressure decay during isovolumic relaxation, which is preload dependent; EDV, end-diastolic volume; EF, ejection fraction; NTG, nontransgenic; PFR/EDV, peak ventricular filling rate normalized to EDV; Power max /EDV, maximal power normalized to EDV reflecting contractility during LV ejection of blood; PRSW, preload recruitable stroke work; SW, stroke work; and τ, isovolumic relaxation time constant, a preload-independent index. *P<0.05 compared with NTG and cTnIS200A. †P<0.05 compared with NTG. n=5.
did not increase EF at all while NTG increased EF from 54.2±4.3% to 73.1±2.5% ( Figure 3G ), indicating that pseudophosphorylation of cTnI Ser200 impairs cardiac reserve in response to incremental heart rate pacing. In contrast to the phospho-mimetic cTnIS200D, the phospho-silenced cTnIS200A does not affect the cardiac reserve.
Inotropic Response to β-Adrenergic Stimulation Was Depressed in TnI Ser200 Pseudophosphorylation Model
To test the impact of cTnI Ser200 modulation on β-adrenergic stimulation, we studied the cardiac response to isoproterenol exposure in both isolated muscles in vitro and intact chambers in situ. Isoproterenol increased developed isometric force in trabecular muscles isolated from NTG and cTnIS200A but had less inotropic effect in cTnIS200D (Figure 4A) . Isoproterenol accelerated isometric relaxation similarly in the muscles from all 3 types of mice, in agreement with the PKA-dependent enhancement of sarcoplasmic reticulum calcium cycling and myofilament desensitization via TnI phosphorylation at its N-terminus ( Figure 4B ). In vivo, cTnIS200D hearts displayed enhanced systolic and diastolic function with isoproterenol but the net response remained lower than controls ( Figure 4C through 4H) . As a result, β-adrenergic stimulation with isoproterenol augmented EF in NTG but not in cTnIS200D mice. Because increased heart rate alone is sufficient to alter cardiac function and isoproterenol increases heart rate (chronotropic effect), we further investigated the cardiac responses to isoproterenol at a fixed heart rate of 600 beats per minute to rule out the interference of frequency-dependent functional changes. The results showed that with fixed heart rate, NTG mice were still able to enhance systolic and diastolic function. However, such systolic enhancement was completely depressed in cTnIS200D ( Figure  III in the Data Supplement). The responses of cTnI-S200A mice to isoproterenol were not significantly different from NTG either in vitro or in vivo. Overall, these results indicate that pseudophosphorylation of cTnI Ser200 depresses inotropic rather than lusitropic responses to β-adrenergic stimulation.
TnI Ser200 Pseudophosphorylation Model Was Resistant to I/R Injury
Removal of cTnI (193-210) by proteolysis during I/R contributes to I/R-related myocardium dysfunction. Our prior in vitro data showed that human cTnI Ser199 hyperphosphorylation appeared to increase cTnI proteolysis mediated by calpain I in vitro, 19 suggesting that cTnIS200D hearts might be more vulnerable to I/R injury. To test the impact in the intact heart, we subjected ex vivo hearts to 30-minute global ischemia followed by 1-hour reperfusion by using a Langendorff perfusion apparatus. After I/R, on average, NTG and cTnIS200A hearts, respectively, recovered 35±15% and 29±8% of their initial LV developed pressure, while surprisingly, cTnIS200D hearts recovered ≈88±8% ( Figure 5A ). Western blot with cTnI McAb 8I-7 (epitope cTnI [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] ) showed that after I/R, cTnIS200D retained more intact cTnI than NTG and cTnIS200A hearts ( Figure 5B and 5C) , and the cTnI degradation is less likely to be detected in cTnIS200D than NTG and cTnIS200A hearts ( Figure 5B ). The result indicates that pseudophosphorylation of cTnI at Ser200 protects cTnI from proteolysis in vivo during I/R, which is specific for the Ser200Asp mutation because the Ser200Ala mutant hearts have an equivalent degree of TnI proteolysis as the NTG. , stimulation frequency 0.5 Hz. A, Peak force developed by trabeculae muscle isolated from mouse hearts. B, The time from the start of contraction to force peak. C, The time from force peak to 90% of force decay. NS indicates not significant. *P<0.05 compared with nontransgenic (NTG) and cTnIS200A. n=5.
TnI Ser200 Mutants Did Not Impact Phosphorylation of Other Sarcomeric Proteins
Because phosphorylation of sarcomeric proteins, such as myosin-binding protein C, desmin, cardiac Tm-binding subunit, and myosin light chain 2, could also impact cardiac function, we assessed whether the global phosphorylation of sarcomeric proteins was altered in the 2 TG mouse models. Pro-Q Diamond staining followed by Sypro-Ruby staining showed the pan-protein phosphorylation level was not significantly changed in any , n=5. C-G, In situ hemodynamic study of cardiac function over paced heart rates from 400 to 700 beats per min. n=5. dP/dt max /iP indicates peak rate of pressure normalized to instantaneous pressure, a preload-independent index of contractility during isovolumic contraction; EDV, end-diastolic volume; PFR/EDV, peak ventricular filling rate normalized to EDV; Power max /EDV, maximal power normalized to EDV reflecting contractility during LV ejection of blood; and τ, isovolumic relaxation time constant, a preload-independent index. P G.F <0.05 indicates significance among the interactions between genotype and pacing frequency. cTnIS200D mice with hyperphosphorylation mutation depressed positive force-frequency relationship both in vitro and in vivo.
of the sarcomeric proteins listed above ( Figure 6A ; Figure IV in the Data Supplement) in either TG mouse model. Among all the known phosphorylation sites on cTnI, Ser23, and Ser24 are the 2 most abundantly phosphorylated sites, and they can significantly impact cardiac relaxation under adrenergic stimulation. Figure 6B and 6C shows that there is no significant difference in cTnI Ser23/24 phosphorylation level between NTG, cTnIS200D or cTnIS200A group either at baseline or after treated with PKA.
DISCUSSION
The major findings of this study are that cTnI Ser200 pseudophosphorylation has divergent effects, impairing basal diastolic function and systolic reserve but par- , stimulation frequency 0.5 Hz. n=5. C-H, In situ hemodynamic measures of cardiac responses to isoproterenol (intravenous injection). n=5. dP/dt max /iP indicates peak rate of pressure normalized to instantaneous pressure, a preload-independent index of contractility during isovolumic contraction; EDV, end-diastolic volume; PFR/EDV, peak ventricular filling rate normalized to EDV; Power max /EDV, maximal power normalized to EDV reflecting contractility during LV ejection of blood; and τ, isovolumic relaxation time constant, a preload-independent index. P G.I <0.05 indicates significance among the interactions between genotype and the concentration of isoproterenol. Transgenic mice cTnIS200D demonstrated depressed cardiac inotropic response to isoproterenol both in vitro and in vivo.
adoxically protecting against I/R injury. The study reveals both physiological and pathophysiological relevance to this post-translational modification, as well as its potential relevance in cardiac disease.
Detrimental Effect of cTnI Ser200 Pseudophosphorylation on Diastolic Function and Systolic Reserve
The finding that pseudophosphorylation at cTnI Ser200 impairs diastolic function in mice in vivo is consistent with our previous finding that human cTnI Ser199 pseudophosphorylation lowers cTnI affinity for actin in vitro. 19 This site resides in the distal C terminus of cTnI, a highly mobile region that has been shown to have large Ca 2+ -induced structural changes during thin filament activation and deactivation.
12 According to the fly-casting model of the cTnI C-terminal mobile region, the cTnI distal C terminus is unstructured in systole when Ca 2+ is bound to a regulatory site on Ca 2+ -binding subunit; however, it senses actin from a large distance and folds on binding to actin when Ca 2+ is absent to initiate relaxation. 11, 12, 20 The effective interaction of actin and cTnI distal C terminus including Ser200 is necessary for full inhibition of contraction and normal relaxation kinetics. 20, 21 Therefore, we speculate that addition of negative charges or a phosphate group by phosphorylation to cTnI Ser200 interferes cTnI sensing and binding to actin and thus impairs diastolic function.
Despite the preservation of overall baseline systolic function, pseudophosphorylation of cTnI Ser200 significantly and negatively affects cardiac systolic reserve, which is manifested under physiological stresses including rapid heart rate and β-adrenergic stimulation. Frequency-dependent enhancement of cardiac muscle contraction and relaxation is an important intrinsic regulatory mechanism in modulating heart function. 22 Although mice usually have less force-frequency reserve than human and larger animals, the positive force-frequency relationship is still present in isolated muscle and in vivo hemodynamic studies. 23, 24 Our results indicate that pseudophosphorylation of cTnI Ser200 impaired force-frequency relationship with depressed enhancement in systolic function. In addition, cTnI Ser200 pseudophosphorylation depresses inotropic response to β-adrenergic signaling, independent of the chronotropic effect of catecholamine. The exact mechanism by which systolic reserve is impaired in this model is not entirely clear. Interestingly, the lusitropic response to β-adrenergic signaling is preserved, which is consistent with the equivalent cTnI Ser23/24 phosphorylation with PKA between cTnIS200D and NTG controls at either baseline or after PKA treatment, given that cTnI Ser23/24 phosphorylation is one of the effectors of lusitropic β-adrenergic signaling.
Unanticipated Protective Effect of cTnI Ser200 Pseudophosphorylation in Hearts Subjected to I/R Injury
The protection of cTnIS200D hearts from I/R injury was striking and was associated with suppression of cTnI proteolysis. These are likely related, given prior data on the adverse impact of cTnI cleavage. First, selective cleavage of cTnI C terminus 17 amino acid residues including this serine residue is generated after I/R, and the remaining cTnI is incorporated into the myofilament leading to depressed myofilament calcium sensitivity and thus cardiac dysfunction. 7 Second, cross talk between protein phosphorylation and its proteolysis has been reported on cTnI 19, 25 although the precise site involved was unknown. Third, protease inhibitor presence in reperfusion solution protects cardiac function after I/R in ex vivo hearts. 26 cTnI Ser200 with pseudophosphorylation is still susceptible to calpain-mediated proteolysis in vitro in the context of recombinant Tn complex, 19 yet it protected the protein from proteolysis ex vivo in the whole heart with I/R. This disparity may imply a role for different accessibility of the protease to cTnI with I/R injury, or a protease other than calpain which cleaves cTnI during I/R, for example, a matrix metalloproteinase-2.
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Implications of cTnI Ser200 Pseudophosphorylation for Human HF Hyperphosphorylation of human cTnI Ser199 was originally found in explanted hearts from patients with HF. 9 cTnIS200D mice, the model of hyperphosphorylation of this site, share many pathophysiological characteristics with patients with HF, in particular the patients with HF with preserved EF. Patients with HF with preserved EF have primarily diastolic dysfunction. Although EF is preserved in HF with preserved EF patients, they have a "dramatic limitation of systolic reserve capacity during stress with blunted increase in EF." 28 Prior studies have demonstrated that both force-frequency relationship and β-adrenergic signaling is depressed, and the positive effect of β-adrenergic stimulation on force-frequency relationship is also diminished or disappeared in HF. 29, 30 It is notable that the phosphorylation level of this site is associated with disease status in a canine model of HF; its phosphorylation level increases abnormally during dyssynchronous HF and returns to normal after resynchronization therapy. 9 
Implications of cTnI Ser200 Pseudophosphorylation for Myofilament Regulation
The distal C terminus of cTnI (cTnI189-210 in human sequence) is suggested to be a highly mobile region with unclear structure and function. Human Ser199 is the only phosphorylatable site found within the region. The present in vivo study together with our previous in vitro study on cTnI Ser199 phosphorylation provide further insight into the function of cTnI C terminus. In vitro, pseudophosphorylation of human cTnI Ser199 decreases cTnI affinity for actin and increases myofilament Ca 2+ sensitivity of force development in skinned human cardiomyocytes in which endogenous cTnI was replaced by recombinant human cTnI Ser199Asp. 19 This may explain why we observed the overall unchanged EF and preload recruitable stroke work with increased dP/dt max /iP during isovolumic contraction and decreased Power max /EDV during the ejec-tion phase. We speculated that increased myofilament sensitivity would lead to an augmented formation of cross-bridges during isovolumic contraction and less cross-bridges recruitable for the stretch activation during ejection phase. For instance, Davis et al 31 suggested that the force required to eject blood against aortic pressure is enhanced by stretch activation of endomyocardium. There are other reports that stretch activation of the myofilament depends on the number of recruitable cross-bridges and cooperativity of the weakly bound nonforce generating cross-bridges transition into strong-binding force-generating states. 32, 33 Furthermore, our finding also agrees with the concept that in the absence of cTnI [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] , the remaining cTnI stabilizes Tm equilibrium position toward an enhanced Ca 2+ -activated-state, 34 a state from which myosin heads start to isomerize to bind actin strongly and push Tm further to generate force.
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Limitations of the Study
Because it is not possible to simply phosphorylate a single site of cTnI in vivo, the overall study is based on the assumption that replacement of serine residue with aspartic acid mimics site-specific phosphorylation in vivo. Although the model may have limitations, aspartic acid has negative charges and a relatively bulky side chain, that is, analogous to phosphorylation adding a phosphate to serine residue. This strategy has been experimentally validated as a suitable way to study site-specific phosphorylation of cTnI. [36] [37] [38] Furthermore, the transgenic model cTnIS200A that carries cTnI Ser200Ala is considered as both a dephosphorylation/ nonphosphorylatable model and serves as a control. cTnIS200A mice have morphologically and functionally normal hearts, suggesting that an amino acid substitution without negative charges or bulky side chain, does not impair cardiac function.
Conclusions
This study is the first investigation of the in vivo impact of phosphorylation of cTnI Ser200 on intact cardiac function. The results indicate that HF-related hyperphosphorylation of cTnI Ser200 depresses diastolic but not systolic function at rest and also diminishes systolic reserve to both chronotropic and catecholamine stimuli, supporting a role of cTnI Ser200 hyperphosphorylation in the development of cardiac dysfunction similar to HF with preserved EF. Additionally, in previous study, hyperphosphorylation of this site was associated with onset of dyssynchronous HF and returned to normal after cardiac resynchronous treatment in a large animal model. 9 Therefore, hyperphosphorylation of human cTnI Ser199 could be seen as a potential biomarker for HF as well as a potential therapeutic target. Paradoxically this phospho site could also mediate some protection from I/R injury. Together, these data provide new functional insights into the post-translational regulation of cTnI and the role of a major modification observed in human HF.
